Table 3.
Expression of CCN3 in Musculoskeletal Tumors Analyzed on Paraffin-Embedded Sections Using the Rabbit Polyclonal Antibody K19M
| Number of cases | Number of positive cases (%) | Relative score | |||
|---|---|---|---|---|---|
| + | ++ | +++ | |||
| Giant cell tumor | 8 | 5* (63) | 3 | 0 | 2 |
| Chondroblastoma | 2 | 2 (100) | 0 | 1 | 1 |
| Chondrosarcoma central | 7 | 7 (100) | 2 | 2 | 3 |
| Peripheral | 2 | 2 (100) | 0 | 0 | 2 |
| Rhabdomyosarcoma embryonal | 6 | 6 (100) | 2† | 2 | 2 |
| Alveolar | 4 | 4 (100) | 0 | 0 | 4 |
| Osteosarcoma Primaries | 9 | 9 (100) | 0 | 2 | 7 |
| Metastases | 4 | 4 (100) | 0 | 0 | 4 |
| Ewing’s sarcoma | 9 | 2 (22) | 0 | 0 | 2 |
*The positivity was referred to the mononuclear cellular component. Osteoclast-like, giant cells are highly positive (+++) in all of the eight samples here analyzed.
†In general, expression was more varied in the embryonal group than in the alveolar group. Ovoid shaped, more differentiated cells stained +++.